Alpha Tau Medical Ltd (DRTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alpha Tau Medical Ltd (DRTS) has a cash flow conversion efficiency ratio of 0.000x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.78K) by net assets ($89.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Alpha Tau Medical Ltd for the company's overall valuation and market capitalisation.
Alpha Tau Medical Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Alpha Tau Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alpha Tau Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alpha Tau Medical Ltd ranked by their cash flow conversion efficiency. See DRTS operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Svolder AB (publ)
ST:SVOL-B
|
0.002x |
|
Grid Dynamics Holdings Inc
NASDAQ:GDYN
|
0.012x |
|
Shenzhen Guangju Energy Co Ltd
SHE:000096
|
0.003x |
|
Waga Energy SA
PA:WAGA
|
0.065x |
|
India Tourism Development Corporation Limited
NSE:ITDC
|
0.014x |
|
SurModics Inc
NASDAQ:SRDX
|
0.013x |
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
-0.060x |
|
MarineMax Inc
NYSE:HZO
|
0.018x |
Annual Cash Flow Conversion Efficiency for Alpha Tau Medical Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Alpha Tau Medical Ltd from 2019 to 2024. View latest Alpha Tau Medical Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $62.67 Million | $-19.78 Million | -0.316x | -48.50% |
| 2023-12-31 | $84.47 Million | $-17.96 Million | -0.213x | +5.94% |
| 2022-12-31 | $105.66 Million | $-23.88 Million | -0.226x | -166.54% |
| 2021-12-31 | $-34.78 Million | $-11.81 Million | 0.340x | -60.52% |
| 2020-12-31 | $-8.43 Million | $-7.25 Million | 0.860x | -97.60% |
| 2019-12-31 | $-193.00K | $-6.91 Million | 35.803x | -- |
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending cl… Read more